July, ArQule, Inc.
|
|
- Beverly Cory Reynolds
- 5 years ago
- Views:
Transcription
1 July, 2012
2 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical trials with the Company s product candidates, including tivantinib ib (ARQ 197), ARQ 621, ARQ 736, ARQ 092, the discovery and development of additional product candidates in the Company s FGFR program, the AKIP drug discovery platform, competitive products, financial operations and results, corporate partnerships and other future business objectives, opportunities and strategies. Forward-looking statements are typically identified by words such as believe, expect, anticipate, intend, outlook, position and similar expressions, or future or conditional verbs such as will, should, would, and could. Forward-looking statements are subject to numerous assumptions, risks and uncertainties. Forward-looking statements speak only as of today, and ArQule assumes no obligation to update them. Actual results may differ materially from forward-looking statements or historical performance due to the factors discussed in this presentation and factors previously disclosed in ArQule s SEC reports. See discussion of Risk Factors in the Company s Annual Report on Form 10-K as filed with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. ArQule s product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials. ArQule and the ArQule logo are registered trademarks of ArQule, Inc. 1
3 ArQule Company Overview: Positioned to Generate Value Focus on Tivantinib (ARQ 197): first-in-class c-met inhibitor Phase 3 randomized trials ongoing: MARQUEE registration trial in 2 nd /3 rd line NSCLC completed patient recruitment in the West (interim analysis by 2012 year-end and final data expected in mid-2013) ATTENTION trial in Asia recruiting, top line data by 2013 year-end Phase 3 randomized trial in preparation: Second line HCC Tivantinib versus best supportive care in Met-high patients Phase 2 randomized trials: Phase 2 CRC trial ongoing, completed recruitment, top line results late 2012 or early 2013 Phase 2 NSCLC K-RAS trial ongoing, to report in 2013 Multiple Phase 3 & 2 randomized trials provide clinical & regulatory milestones in 2012 and
4 ArQule Financial Profile Cash balance Cash and marketable securities at Mar 31, 2012 $ 100 Mil Net use of cash guidance 2012 $ Mil Cash and marketable securities 2012 end guidance $ Mil* Stock data Shares outstanding at Apr 30, Mil Fully diluted shares outstanding at Apr 30, Mil Key recent sources of funding Share offerings (Jan 2011 and Apr 2012) $ 103 Mil Partnership milestones 2007/2012 (excluding research support) $ 158 Mil *Note: Includes net proceeds of ~$56 Mil from April 2012 common stock offering not reflected in cash and marketable securities at March 31,
5 Tivantinib Partnerships: Enabling Broad Clinical Development Key terms Daiichi Sankyo (DS) co-development worldwide, except Asia $60 Mil upfront, $560 Mil potential milestones, tiered double-digit royalties DS has all ex-asia commercial rights, ArQule has US co-commercialization Kyowa Hakko Kirin (KHK) in Asia* $30 Mil upfront, $93+ Mil potential milestones, mid teens/low 20s royalties KHK has exclusive development and commercial rights in its region Financial implications DS and ARQL fund 50/50 development costs ex-asia; ARQL to fund its 50% of Ph 3 costs exclusively with milestones and royalties, if necessary KHK to fund 100% development/commercialization costs in Asia * Asia for contractual purpose is defined as: Japan, China, S. Korea, Taiwan and Hong Kong. 4
6 Tivantinib Development Program: Pipeline in a Drug Research Pre-clinical Phase 1 Phase 2 Phase 3 Approved NSCLC Tivantinib + erlotinib (worldwide ex-asia) MARQUEE NSCLC Tivantinib + erlotinib (Asia) ATTENTION Registration HCC (hepatocellular) Tivantinib Single Agent Colorectal Tivantinib + irinotecan/cetuximab Randomized NSCLC Tivantinib + erlotinib KRAS mutations (U.S.) Tivantinib + Sorafenib* & Tivantinib ib + Gemcitabine** CRADA trials (NIH) Open Label Signal Generation *Sorafenib-sensitive tumors: Hepatocellular, Renal Cell Carcinoma, NSCLC, Melanoma, Breast **Gemcitabine-sensitive tumors: Pancreatic, Uterine, Ovarian, Breast, NSCLC 5
7 Tivantinib in NSCLC: Phase 3 MARQUEE Registration Trial in 2/3 rd Line, Under SPA (Worldwide ex-asia, Daiichi Sankyo) NSCLC Inoperable locally adv/ metastatic disease Non-squamous histology only 1-2 regimens prior chemo (no prior EGFR TKI) Prior adjuvant/ maintenance therapy allowed R A N D O M I Z E Erlotinib 150 mg PO QD + Tivantinib 360 mg PO BID 28-day cycle Erlotinib 150 mg PO QD + Placebo BID 28-day cycle Parameters: ~1,000 patients ~ 200 sites in ~20 countries Stratify by EGFR and KRAS mutation status Interim analysis to be performed at 50% of events 1 Endpoint OS (ITT population) 2 Secondary Endpoints incl: - PFS (ITT population) - OS and PFS in EGFR WT patients - Safety and toxicity - QOL/FACT-L - Biologic sub-groups 6
8 Tivantinib in NSCLC: Enrolling Phase 3 ATTENTION Registration Trial in 2/3 rd Line (Asia, Kyowa Hakko Kirin) NSCLC Inoperable locally adv/ metastatic disease Non-squamous histology only Wild-type EGFR Prior adjuvant/ maintenance therapy allowed Parameters: aa etes ~ 460 patients ~ 50 sites in Japan, Korea and Taiwan R A N D O M I Z E EM*: Erlotinib ib 150 mg PO QD + Tivantinib 360 mg PO BID 28-day cycle OR PM**: Erlotinib 150 mg PO QD +Tivantinib 240 mg PO BID 28-day cycle EM: Erlotinib 150 mg PO QD + Placebo BID 28-day cycle OR PM: Erlotinib 150 mg QD +Placebo BID 1 Endpoint OS (ITT population) 2 Secondary Endpoints incl: - PFS (ITT population) - Objective response rate - Adverse events *Extensive metabolizer patients **Poor metabolizer patients 7
9 In Ph 2 NSCLC Trial, Tivantinib+Erlotinib Nearly Doubles Median PFS in Non-Squamous Cell Histology Patients* PFS (Investigator Assessed) HR=0.71 (95% CI: 0.46, 1.10) P=0.12 Adjusted HR=0.61 (95% CI: 0.47, 0.98) P<0.05** Overall Survival HR=0.72 (95% CI: 0.6, 1.3) P=0.18 Adjusted HR=0.58 (95% CI: 0.34, 0.99) P<0.05** Propor rtion of patients progression-free e Erlotinib + Tivantinib 18.9 wks (n=58) Erlotinib + Placebo 9.7 wks (n=59) Time from randomization (weeks) tients surviving Proportion of pat Erlotinib + Tivantinib 43.1 wks (n=58) Erlotinib + Placebo 29.4 wks (n=59) Time from randomization (weeks) * Data presented in ASCO plenary session June 2010 ** Cox regression model 8
10 Tivantinib in HCC: Dual Approach with Ph 2 Monotherapy & Expanded Ph 1 Combination with Sorafenib Dual development approach Single agent Combination with sorafenib Rationale single agent c-met dysregulated in HCC Silencing of c-met expression inhibits growth of HCC cell lines Rationale combination therapy In vitro/vivo synergy demonstrated with tivantinib + sorafenib Oral dosing enables convenient co-administration Study design Ph 2 monotherapy Second line setting Randomized, double-blind ~ 100 patients 1º endpoint TTP Study design Ph 1 combination Open label single arm ~ 40 patients Safety of tivantinib + sorafenib ASCO 2010/11 reports 2010 single agent tolerated, with preliminary signs of efficacy 2011 combination well tolerated, with preliminary signs of efficacy 9
11 Tivantinib in HCC: Successful Single Agent, Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2 nd Line HCC HCC Second line setting, single agent against best supportive care Randomized, doubleblind Parameters: ~ 100 patients ~ 23 sites in 5 countries R A N D O M I Z E Tivantinib 360 or 240 mg BID Best Supportive Care 1 Endpoint TTP 2 Secondary analysis incl: - Viral status - Time on front line therapy - Safety profile by dose sub-group - Biologic sub-groups by IHC defined c-met status 10
12 Tivantinib in HCC: Key Findings from Randomized, Controlled Phase 2 Single Agent Trial Study met primary endpoint in second-line HCC (ITT population), with statistically significant 56% improvement in time-to-progression (HR = 0.64, log rank p-value = 0.04) Major improvements in MET+ patients OS (7.2 mos. vs. 3.8 mos., HR=0.38, log rank p-value=0.01) 01) TTP (2.9 mos. vs. 1.5 mos., HR=0.43, log rank p-value=0.03) PFS (2.4 mos. vs. 1.5 mos., 0.45, log rank p-value =0.02) Efficacy similar in both tivantinib dosing subgroups (360 milligrams BID and 240 milligrams BID) AEs reported at similar rates in both arms except for higher incidence of fatigue and hematologic events, which declined with dose reduction Phase 3 trial among previously treated HCC patients with MET-high tumors being planned 11
13 MET as a Prognostic Factor (Patients on Placebo) Median OS Patients Events MET Dx Low MET Dx High HR: 2.94 (95% CI: ) Log Rank: P=0.02 Data presented at ASCO June 2, 2012
14 Improved TTP in MET Diagnostic High Group Median TTP Patients Events Tivantinib 11.7 wks Placebo 6.1 wks HR: 0.43 (95% CI: ) Log Rank: P=0.03 PFS: HR 0.45 (95% CI: ) 0 Log Rank: P= DCR: 50% on tivantinib (28-72) vs 20% (4-48) Data presented at ASCO June 2, 2012
15 Improved OS in MET Diagnostic High Group Median OS Patients Events Tivantinib 7.2 mos Placebo* 3.8 mos HR: 0.38 (95% CI: ) Log Rank: P=0.01 *8 MET Dx High patients crossed-over, 5 remained on open-label tivantinib for at least 6 weeks (1 non-evaluable at cut-off date) Data presented at ASCO June 2, 2012
16 OS of Selected Subgroups in ITT Patients / Events Favors Tivantinib Favors Placebo Tivantinib Placebo HR (95% CI) MET Dx High 22/17 15/ ( ) 0 81) Low 27/20 13/ ( ) Starting Dose 240mg BID 33/21 36/ ( ) 360mg BID 38/35 36/ ( ) Vascular Invasion Yes 22/21 13/ ( ) No 49/35 23/ ( ) Distant Metastasis Yes 43/34 28/ ( ) No 28/22 8/ ( ) ECOG PS 0 41/29 21/ ( ) 1 30/27 15/ ( ) HBV Pos* 16/15 5/ ( ) HCV Pos (HBV Neg) 31/23 14/ ( ) HBV / HCV Neg / Neg 24/18 17/ ( ) Baseline AFP (IU/mL) <200 37/30 15/ ( ) /23 21/ ( ) Prior sorafenib therapy 60 days 15/13 4/ ( ) >60 days 55/42 29/ ( ) *5 HBV Pos patients are also HCV Pos Data presented at ASCO June 2, 2012
17 Tivantinib in Colorectal: Enrolling Ph 2 Combination with Irinotecan + Cetuximab CRC Inoperable locally adv/metastatic dz. >1 prior chemo KRAS wt R A N D O M I Z E Irinotecan/Cetuximab + Tivantinib 360 mg BID Irinotecan/Cetuximab + Placebo BID Parameters: ~ 150 patients ~ 25 sites in 5 countries 1 Endpoint PFS 2 Secondary Endpoints incl: - OS - ORR - Safety profile - Biologic sub-groups 16
18 Summary Tivantinib: Much Data Available, More to Come Demonstrated active as single agent and in multiple combinations Demonstrated efficacy in NSCLC and HCC in randomized Ph 2 trials Two NSCLC Ph 3 trials (MARQUEE and ATTENTION) ongoing One additional Ph 3 (HCC) in planning Expected milestones 2012 and 2013 Interim analysis (~#370 events) of Ph 3 NSCLC MARQUEE Randomized data from Ph 2 CRC trial (late 2012/early 2013) Initiation of Ph 3 HCC trial in 2 nd line HCC Complete recruitment ATTENTION Final analysis MARQUEE 17
Jefferies 2014 Global Healthcare Conference. June 5, 2014
Jefferies 2014 Global Healthcare Conference June 5, 2014 ArQule, Inc. Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationTivantinib Overview April 2016
Tivantinib Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationCorporate Overview. April 2016
Corporate Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationSecond Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
Second Line Therapy in Hepatocellular Carcinoma (HCC): A Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197) C Porta, I Borbath, L Rimassa, B Daniele, S Salvagni, JL Van Laethem, H Van
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationBroad Spectrum, Targeted Approaches To Cancer Treatment
SELECTIVELY KILLING CANCER CELLS Broad Spectrum, Targeted Approaches To Cancer Treatment Safe Harbor The presentation made during this meeting and other statements by ArQule may contain forward-looking
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationInvestor Presentation February 2016
Investor Presentation February 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationJefferies 2015 Global Healthcare Conference. June 2015 CORP OVERVIEW
Jefferies 2015 Global Healthcare Conference June 2015 CORP OVERVIEW Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationCalithera Biosciences. January 2019
Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More information